

Excipients Use in Parenteral and Lyophilized Formulation Development

Yasir Mehmood^{1, 2, *}, Umer Farooq¹

¹Faculty of Pharmacy, University of Central Punjab, Lahore, Pakistan ²Ameer & Adnan Pharmaceuticals (pvt.) Limited, Lahore, Pakistan

Email address

yasirmehmoodamjad@gmail.com (Y. Mehmood)

To cite this article

Yasir Mehmood, Umer Farooq. Excipients Use in Parenteral and Lyophilized Formulation Development. *Open Science Journal of Pharmacy and Pharmacology*. Vol. 3, No. 3, 2015, pp. 19-27.

Abstract

Excipients are the integral part of pharmaceutical product development to achieve the desired product profile (stability and efficacy). This review deals with understanding of the physicochemical properties of excipients used in parenteral formulation development for solution, suspension and lyophilized drug products. However, in spite of proper excipients selection, judicious use during formulation, manufacturing process based on their critical property that is also important to avoid negative effects such as loss of drug solubility, activity and stability. This paper deals with proper selection of excipients in lyophilized and parenteral drug products which gives high critical temperature, good bulking properties avoiding melt back and collapse with improved dried product appearance. We have also emphasized on appropriate selection of excipients for solution, suspension injectable dosage forms and linking their physiochemical properties with optimum manufacturing method with suitable case studies. This review will highlight various excipients related issues, optimizing product performance with documented references and practical approaches based on scientific justification. The reader will gain better understanding of excipients complexity during stability studies and resolving problems with practical approach.

Keywords

Excipients, Parenteral, Lyophilized, Suspension, Formulation Development

1. Introduction

Excipients are typically the major components in a drug product. Many formulations contain only a small percentage of the active drug molecules. Pharmaceutical excipients or additives are compounds added to the finished drug products to serve a specific function. They are added to increase bulk, aid manufacturing, improve stability, enhance drug delivery and targeting, and modify drug safety or pharmacokinetic profile. Ingredients that are used during drug product manufacturing, but may not be present in the finished drug product are also considered excipients (examples include water for lyophilized products, and inert gases in the head space of containers)⁽¹⁾. In recent years the "functionality" of excipients in a dosage form (similar to the pharmacological activity of an active pharmaceutical ingredient or drug substance) has been recognized by USP & European Pharmacopoeia.

Excipients are traditionally referred to as inactive or inert

ingredients to distinguish them from active pharmaceutical ingredients. Excipients may not be as inert as the term inactive suggests. Due to safety issues, several countries have restrictions on the type or amount of excipients that can be included in the formulation of parenteral drug product. For example, in Japan, U.S.A and EU amino mercuric chloride or thiomersal use is prohibited, despite the presence of these excipients in products in other regions ⁽²⁾.

As defined in Ph. Eur. and the British Pharmacopeia (BP), "Parenteral preparations are sterile preparations intended for administration by injection, infusion, or implantation into the human or animal body." In the present article, only sterile preparations for administration by injection or infusion into the human body will be surveyed ^(3,4). Injectable products require a unique formulation strategy. The formulated product must be sterile, pyrogen-free, and, in the case of solution, free of particulate matter. No coloring agent may be added solely for the purpose of coloring the parenteral preparation. The formulation should preferably be isotonic, and depending on the route of administration, certain excipients are not allowed. The injected drug by-passes natural defense barriers; hence, for any given drug, the risk of an adverse event may be greater or the effects difficult to reverse if administered as an injection rather than a non-Parenteral route. For this reason ultra high purity grades of excipients are available for parenteral administration. Sterility requirements demand that excipients are able to withstand terminal sterilization or aseptic processing. These factors limit the choice of excipients available ⁽²⁾.

Excipients which are already present in marketed formulations and accepted by the Food and Drug Administration (FDA) as safe, increases the assurance to a formulator that these excipients will probably be safe for a new drug product. But, this does not give complete assurance when combined with other excipients or drug molecules as this may lead to unwanted potentiation or synergistic toxic effects. However, regulatory bodies may favorably view an excipients previously approved in an injectable dosage form, and will require less safety data. A new additive in a formulated product always requires additional studies, adding to the cost and timeline of product development. Importantly, inclusion of excipients in the GRAS (Generally Recognized as Safe) list or pharmacopoeia does not mean that the excipients have been deemed safe by the FDA for use in parenteral products.

2. Excipients Used in Lyophilization

2.1. Bulking Agents and Lyoprotectants

Bulking agents forms the bulk of the lyophilized product and provide an adequate structure to the cake. These are generally used for low dose (high potency) drugs that do not have the necessary bulk to support their own structure. These are particularly more important when the total solid content is less than 2 %⁽⁵⁾. In such cases, a bulking agent is added to the formulation matrix. The structure of the lyophilized cake is important, since proper cake formation leads to proper pore formation that provides the means for vapor to escape from the product during the drying cycle⁽⁶⁾ Lyoprotection defined as the stabilization and prevention of the degradation of a molecule both during freeze-drying and afterwards, during storage. Among disaccharides, sucrose and trehalose appear to be the most commonly used. In comparison to sucrose, trehalose seems to be a preferable lyoprotectant, because it has a less hygroscopicity, very low chemical, reactivity and inally, higher glass transition temperature (Tg)^(7,8,9). Critical temperature is the temperature above which the freeze-dried product loses macroscopic structure and collapses during freeze drying. Therefore, the excipients which provide higher critical temperature are preferred for lyophilization.

Mannitol: It is the most commonly and widely used excipients in the lyophilized products. Mannitol has a very high eutectic melting temperature (-1.4°C) after crystallization

and is processed well in lyophilization. Crystallization of the bulking agent, however, might adversely affect the physical stability of the product in certain instances, for which, an amorphous bulking agent is preferred ⁽¹⁰⁾.

Lactose: It is a good bulking agent but is a reducing sugar and may undergo Maillard reaction with proteins leading to instability of the formulation⁽¹¹⁾. The critical temperature of 1% lactose is -32°C.

Table 1. Critical process temperatures of various excipients used in
Lyophilization (14)

Excipients	Tg ^{,0} C	Tc ⁰ C	references
Bulking Agent			
Sucrose	-32, -35	-34,-32	(14, 15, 16)
Lactose	-28	-31, -32	(5, 6, 17)
Trehalose	-27, -29	-29.5, -34	(5, 6, 8)
Mannitol	-35, -28		(5, 8)
Sorbitol	-46	-45	(6, 8, 18)
Glucose	-43	-40, -41.5, -43	(6,7,19)
Rafinose	-27	-26	(9)
Glycine	-62		(20)
Histidine	-33		(5)
PVP (K40)	-20	-23	(6, 8, 9)
Buffering Agent			
Sodium citrate	-41		(5)
Sodium	-45		(5)
phosphate			
Tris base-65	-51		(5)
Tris acetate	-54		(5)
Tris HCl -65	-65		(5)
Tonicity Modiier			
Dextrose	-44		(8)
Dextran	-10	-9, -10,	
Ficoll	-19	-19.5, -20	
Gelatin	-9	-8	
Hydroxyethyl		-5	(21)
starch			

Sucrose: It is having similar collapse temperature i.e -31°C (2%) as of lactose but it is not a reducing sugar and does not undergo Maillard reaction ⁽¹²⁾. Sucrose has a higher density as compared to lactose which can cause slight collapse during drying.

Polyethylene glycol (PEG): It provides good cake structure and increases viscosity of water ⁽¹³⁾. The 2% solution of PEG has a critical temperature of -22°C. Apart from lyophilization it is also used as a co-solvent and viscosity modifier in Parenteral including ophthalmics.

Polyvinyl pyrollidone (PVP): The low-molecular grades, Povidone K 12 and K 17 are used as solubilizing agents, dispersants and crystallization inhibitors, particularly for injectable. This application is used in particular for antibiotics in solution or in lyophilized form. Povidones with higher K-values may not be administered parenterally as, due to their high molecular weights, they cannot be excreted by the kidneys and hence accumulate within the body. The povidone grades K12 and K 17 are used as solubilizers in parenteral applications. In addition Polyvinyl pyrollidone also provides cryo-protection to the product. The C-grades are supplied with low endotoxin levels ("pyrogen-free"). Bovine Serum Albumin (critical temperature of 0.5% solution of BSA is -9°C), Dextran (critical temperature of 2.0% solution of Dextran mw 9500 daltons is -12°C) due to its longer chain polymer of glucose gives higher viscosity and higher critical temperature. In addition other excipients which can be used for lyophilization are listed in Table 1 along with their critical process temperatures.

2.2. Buffering Agents

Control of pH is critical to avoid degradation of drug during processing, storage and reconstitution, thereby necessitating addition of buffering agent in the lyophilized formulation. The choice of buffer depends on the pH stability profile of active ingredient as drug needs to be reconstituted and stored for some time before it could be administered to the patient. For this purpose, the pH of maximum stability of drug should be known and maintained. Selection of a suitable buffer and its concentration is important for sensitive molecules.

The buffering agent should have a high collapse temperature, be non-volatile and have a high glass transition temperature (Tg). A high collapse temperature would facilitate a faster primary drying, and its non-volatile nature would prevent pH drift, that might be detrimental to the product stability. Additionally, a high glass transition temperature (Tg) would ensure stability during storage. In this context, acetate buffer is not used due to its volatile nature, as it can be partially lost during lyophilization. Crystallization of buffer components can also lead to a drastic shift in pH, resulting in degradation of the active component. Sodium and potassium phosphate salts are not often used in the lyophilization, since these crystallize during cooling and in frozen solution, which leads to a decrease in pH of about 4 units. Shalave et al. studied citrate, succinate and tartrate buffer for their crystallization behavior and its effect on pH of the formulation. Citrate buffer was found to be the most preferred as it remained amorphous, with the shift in pH being minimal, in comparison to succinate and tartrate, which crystallized during lyophilization. Tris buffer is known to release formaldehyde in peptide formulations stored at 70°C"pH memory" is a term used to denote the relationship between pH-activity and pH stability profiles, in the solution and dried state respectively, as the pH of the solution before drying has an impact on the rate of chemical reactivity in the resulting amorphous material. Commonly used buffers in the Parenteral formulations are Acetate, Citrate, Tartrate, Phosphate, Triethanolamine (TRIS).

3. Excipients Used in Liquid Injection

3.1. Tonicity Adjusting Agents

Parenteral formulations should be isotonic with human plasma so as to avoid damage to the tissues. However, not all drugs at their recommended dosage are isotonic with blood, thus requiring the addition of a tonicity adjusting agent to the formulation. The most commonly used tonicity agent is dextrose, while others, such as glycerol and sodium chloride are less commonly used. Other commonly used tonicity adjusting agents are Glycerin and Mannitol.

3.2. Preservatives: Antioxidants, Antimicrobial and Chelating Agents

The antioxidants are used to prevent/minimize the oxidation reaction of the drug or excipients over the shelf life of the product whereas antimicrobial agents are used to prevent the growth of micro-organisms in the drug product. The most commonly used antioxidants in the sterile formulations are Ascorbic acid, Acetylcysteine, Sulfurous acid salts (bisulfite, metabisulfite), Monothioglyercol etc. The commonly used antimicrobial agents are Phenol, Metacresol, Benzyl alcohol, Parabens (methyl, propyl, butyl), Benzalkonium chloride, Chlorobutanol, Thimerosal,

Phenylmercuric salts (acetate, borate, nitrate) etc. In addition to the antioxidant and antimicrobial a chelating agent can be deined as a substance whose molecules can form several bonds to a single metal ion. Against the general understanding several single dose preparations contain preservatives due to legacy.

3.3. Solubilizing Agents

The agents which help in dissolving or increase the drug solubility into the formulation are known as solubilizing agents, the solubilizing agents can be broadly classified into surfactants and co-solvents. The surfactants increase the dissolution by reducing the surface tension of the drug substances whereas, co-solvents are defined as a solvent that in conjunction with another solvent can dissolve a solute. Few examples of surfactants are Polyoxyethylene sorbitan monooleate (Tween Sorbitan monooleate 80), Polyoxyethylene sorbitan monolaurate (Tween 20), Lecithin, Polyoxyethylene polyoxypropylene copolymers (Pluronics). Examples of co-solvents are Propylene glycol, Glycerin, Ethanol, Polyethylene glycol (300 and 400), Sorbitol, Dimethylacetamide and Cremophor EL etc.

3.4. Complexing and Dispersing Agents

Complexation is sometimes used to improve the solubility of drug in the solvent especially water. Cyclodextrins have emerged as very effective additive compounds for solubilizing hydrophobic drugs. In the parenteral_b dosage form, modified cyclodextrins, such as hydroxypropylcyclodextrin and sulfobutylether- -cyclodextrin have been reported to solubilize and stabilize many injectable drugs, including dexamethasone, estradiol, interleukin-2, and other

proteins and peptides without apparent compatibility problems.

Table 2.	Excipients	used in	different	drug	formulations.
nuone 2.	Excipients	uscu m	ujjereni	urus.	for manufons.

Drug	Category	Excipients	Route administration
		h-cyclodeytrin Lactose	
Alprostadil	Erectile dysfunction	b cyclodexiilli, Edetose	Intracavernosal
Alprostadil	Erectile dysfunction	Lactose, Sodium citrate, Benzyl alcohol	Intracavernosal
Azathiopurine sodium	Immunosuppressive antimetabolite;	-	IV bolus, IV infusion
	rheumatoid arthritis		
Azithromycin	Antibiotic	Citric acid	IV infusion
Aztreonam	Antibiotic	L- arginine	IM, IV bolus, IV
			infusion
Carmustine	Antineoplastic		IV infusion
Cefazolin sodium	Antibiotic		IM, IV bolus, IV
Cofegalin andium	Antibiotic		Infusion
Celazolin sodium	Antibiotic		INI, IV DOIUS, IV
Chlorothiazide sodium	Diuretic and	Mannitol Thiomersal	IV bolus IV infusion
Chlorothazide Sodium	hypertensive	Wanniton, Thiomersar	
Cisplatin	Antineoplastic	Mannitol, Sodium chloride	IV infusion
Colfosceril palmitate	Prevention and	Cetyl alcohol, Tyloxapol,	Intratracheal
r in the second s	treatment of	Sodium chloride	
	Respiratory disease syndrome in low birth weight infente		
Cyclophosphamide	Antineoplastic	Mannitol	IM, IV bolus, IV infusion IP Intrapleural
Dactinomycin	Antibiotic	Mannitol	IV bolus. IV infusion
Dantrolene sodium	Muscle relaxant	Mannitol	IV bolus, IV infusion
			over 1 hr
Daunorubicin Hcl	Antibiotic	Mannitol	IV infusion
Dexrazoxane	Cardioprotective agent		IV
Diltiazem	Antianginal	Mannitol	IV bolus, IV infusion
Doxorubicin HCl	Antineoplastic	Lactose, Methyl paraben	IV
Etoposide phosphate	Antineonlastic	Sodium citrate Dextran	IV infusion over 30-60
Etoposide prospidie	Munooplastic	40	min
Epoprostenol sodium	Antihypertensive	Mannitol, Sodium chloride	IV infusion
Ethoormoto codium	Divertia	Glycine	Slow W bolug W
Einacrynate sodium	Diuretic	Mannitol	Slow IV bolus, IV
Fludarahina phosphata	Antineoplastic	Mannital	Infusion over 30 min
Ganciclovir sodium	Treatment of CMV	Wallintor	IV infusion at 5mg/kg
Galerelovii sodiulii	retinitis in Immune		over 1
	compromized patient		Hr
Gemcitabine Hcl	Antineoplastic	Mannitol, Sodium acetate	Mannitol Sodium
			acetate IV infusion over 30 min
Hemin	Treatment of acute	Sorbitol, Sodium	IV infusion
	intermittent porphyria related to mensuration	carbonate	
Hydromorphone Hel	Opioid analgesic	-	IV. IM. SC
Indomethacin sodium	NSAID		IV bolus

Buffers added to a formulation to adjust and stabilize pH and optimize drug solubility and stability, for parenteral preparations, it is desirable that the product pH be close to physiologic pH. Selection of a buffer concentration (which contributes to the ionic strength of the formulation) and a buffer species is important. For example, citrate buffers in the range of 5–15 mM are typically used in formulations but increasing the buffer concentration to 50 mM will result in excessive pain on sub-cutaneous injection and toxic effects due to chelation of calcium in the blood. Table 6 lists buffers and chemicals used for pH adjustment and maintenance of the drug product pH range, phosphate, citrate, and acetate are

the most common buffers used in Parenteral products. Citrates are common buffers that serve a dual role as chelating agent. Lactate and tartrate are occasionally used as buffer systems. Acetates are good buffers at low pH, but they are not frequently used for lyophilization because of the potential sublimation of acetates.

Table 3. List of excipients used in lyophilized formulations.

IansopraceleProto pump inhibitorManitol, Keglumine, Sodium AjvoxideIVLevothyroxine sodiumIormone replacementManitol, SodiumMa IVMelphalan HelAntineoplasticProgylene glycol, chtyl alcohol, sodium citrateNi infusion over 15-20 minMethokrital sodiumAnteneoplasticProgylene glycol, chtyl alcohol, sodium citrateNi infusion over 15-20 minMethokrital sodiumAnteneoplasticIormone replacementSodium phosphate, carbonatNi Vb olus, IVMethyl prednisoloneAnteneoplasticLactose, Enzyl alcoholInfusionMethyl prednisoloneAntineoplasticLactose, Enzyl alcoholNi Nb olus, IV infusionMitomycinAntineoplasticLactoseVi finfusionPamidronate disodumIndinoplasticManitolNi No bolus, IVPamidronate disodumIndinoplasticIormone replacementSolium phosphate, infusionPipeuronium bromideIngresoryNi InfusionNi IorikonPipeuronium bromideIngresoryIorgening agentNi IorikonPresoryAntidop for vordose due to mationVi finisonNi InfusionSteptosocinAntidop for vordose due to antele to antele to infusionVi InfusionPipeuronium bromideAntidop for vordose due to antele to antidop for vordoseVi fifusionPipeuronium bromideAntidop for vordose due to antele to to ontationSodium citratePipeuronium bromideAntineoplasticVi fifusionTindeptasticSo	Drug	Category	Excipients	route of administration
Sodium hydroxide Levoltyroxine sodium Hormone replacement Manniel, Sodium M. /V Melphalan Itel Antineoplastic Prosphere tribusic min Methohexital sodium Antineoplastic Prosphere glycol, ethyl min Methohexital sodium Anesthetic Anthydous sodium (irate) IV. JM Methohexital sodium Anesthetic Sodium phosphate, choose sodium (irate) M. IV bolus, IV infusion Methohexital sodium Antineoplastic Itactose, Benzyl alcohol IV bolus, IV infusion Methohexital sodium Antineoplastic Itactose, Renzyl alcohol IV bolus, IV infusion Methohexital sodium Antineoplastic Itactose Sodium phosphate, infusion Methohexital sodium Antineoplastic Itactose IV bolus, IV infusion Prosphere glycol, dubit Mannitol Mannitol IV bolus, IV infusion Prosphere tribut Antineoplastic Itanitoi Infusion Prosphere tribut Antineoplastic Glycine IV bolus, IV infusion Prosphere tribut Antineoplastic Glycine <thiv bolus,="" infusion<="" iv="" td=""><td>Lansoprazole</td><td>Proton pump inhibitor</td><td>Mannitol, Meglumine,</td><td>IV</td></thiv>	Lansoprazole	Proton pump inhibitor	Mannitol, Meglumine,	IV
Levoltyroxine sodiumInfomone replacementManital, SodiumM, IVMelphalan HelAntinooplasticProgvince glocal, ethyInitiation over 15-20 nainMethohexital sodiumAnestheticProgvince glocal, ethyInitiation over 15-20 nainMethohexital sodiumAnestheticVin Matsion over 15-20 nainMethohexital sodiumAnestheticAnthydross sodiumIVMethohexital sodiumAnestheticManitolVin MuscoMethohexital sodiumAnthectrialManitolIVMetonidazoleAnthectrialManitolVir bolus, IVMetonidazoleAntineoplasticLactose, Benzyl alcoholVin fusionPamidronate disodiumInhibiton of bone resorptioManitolVir bolus, IVPanidronate disodiumInhibiton of bone resorptioManitolVir bolus, IVProtostatinAntineoplasticLactoseVir bolus, IVPhentolamine mesylateAntineoplasticNotolaVir bolus, IVPipeuronitum bromideInga acting neuromuscular eutonoscular anteronoscular eutonoscular eutonoscular anteronoscular eut	-		Sodium hydroxide	
Melphalan HelAntinocolasticProsphere glycol, chyl Protylene glycol, chyl alcohol, sodium citratieMelhohexital sodiumAnestheticAnthylrous sodiumIV, IMMethol, prednisoloneHormone replacementSodium phosphate, Lactose, Benzyl alcoholIV, IMMethyl prednisoloneHormone replacementSodium phosphate, Lactose, Benzyl alcoholIV, IMMethyl prednisoloneAntinecolasticMamitolV bolus, IVMetronidazofeAntinecolasticLactose, Benzyl alcoholIV bolus, IV infusionMetronidazofeAntinecolasticMamitolV bolus, IVPranidonate disodumInhibitorio of bone resorptionMamitolV bolus, IVPentostatinAntinecolasticMamitolIV bolus, IVPhotolamine mesylateLong acting neuromuscular neuromuscular neuromuscular antotochinesterase-IV bolus, IV infusionPralidoxime chlorideAntibacterialGlycineIV bolus, IV infusionIVRemifentanil HelAntalgesicGlycineIV bolus, IV infusionTazobatam sodium and Piperacillin sodiumAntibacterialSodium cirateIV infusionThiopental sodiumAntibacterialSodium carbonateIV infusionTiapequellin disodiumAntibacterialSodium carbonateIV infusionPraidoxime chlorideAntibacterialSodium carbonateIV infusionTiapequellin disodiumAntibacterialSodium carbonateIV infusionTiapequellin disodiumAntibacterialMamitol, IC irit acid <td< td=""><td>Levothyroxine sodium</td><td>Hormone replacement</td><td>Mannitol, Sodium</td><td>IM, IV</td></td<>	Levothyroxine sodium	Hormone replacement	Mannitol, Sodium	IM, IV
Melphalan Hel Antineoplastic Providence, Diluent: Water, Providence, glycol, chyl, in anio (1992) IV infusion (1992) Metholexital sodium Anesthetic ackola, sodium (1994) IV Mathian (1994) Metholexital sodium Iv Infusion IV Mathian (1994) IV Mathian (1994) Methol predinisolom Iv Metholex, IV infusion Methol predinisolom Iv Mathian (1994) IV Mathian (1994) Methol predinisolom Antinoplastic Laccose, Benzyl alcohol IV Mathian (1994) Methol predinisolom Antinoplastic Laccose, Benzyl alcohol IV Mathian (1994) Panidonate disodium Antinoplastic Laccose, Benzyl alcohol IV mathian (1994) Panidonate disodium Antinoplastic Laccose, Benzyl alcohol IV mathian (1994) Panidonate disodium Antinoplastic Isour Y Mathian (1994) Infusion Panidonate disodium Antinoplastic Isour Y Mathian (1994) Infusion Pipecuronium bromide Log acting aresthetic Antiolof for overdose (1994)			phosphate tribasic	
Inderstandmin alcoho, sodium citrateMethohexital sodiumAnestheticAnhydrous sodiumIV. IMactonatecatonatecatonateactonatesuccinate SodiumAntisore replacementSodium phosphate, InflusionIN IV bolus, IVMethohexital SodiumAntisore replacementSodium phosphate, InflusionIN IV bolus, IV infusionMetronidazofeAntisore replacementSodium phosphate, InflusionIN IV bolus, IV infusionMetronidazofeAntisore replacementManitolIV bolus, IV infusionMetronidazofeAntisore plasticManitolIV bolus, IVPanidronate disodiumInhibitorio of boneManitolIN IV bolus, IVPanidronate disodiumInhibitorio of boneManitolIN IV bolus, IVPentostanine mesylateAntisore resprisonIN IN bolus, IVInfusionPhentolamine mesylateAntisore resprisonIV bolus, IV infusionIN IV bolus, IVPiecuronium bromideAntisore for overdosce-IV bolus, IV infusionPradidoxime chlorideAntisore for overdosce-IV bolus, IV infusionSteptozocinAntisore for overdosce-IV bolus, IV infusionAntisore for overdosce-Citri acidIV bolus, IV infusionAntisore for overdosce-IV infusionIV infusionAntisore for overdosce-IV infusionIV infusionAntisore for overdosce-IV infusionIV infusionAntisore for overdosce-IV infusionIV infusion<	Melphalan Hcl	Antineoplastic	Povidone, Diluent: Water,	IV infusion over 15-20
Achebecial solum Aeshcia Analytore solum Val Material Metholexital solum Hornone replacement Solum phosphate, mitusion Mal Volus, IV Succinate Solum Lacose, Benzyl alcohol Mitusion infusion Metholexital Solum Antineoplatic Lacose, Benzyl alcohol Witosion Mationycin Antineoplatic Lacose, Benzyl alcohol Witosion Pamidonate disodium Inhibition of Bone Mannitol Witosion Pamidonate disodium Antineoplastic Mannitol Witosion Pentostatin Canage and presension Slow V bolus, IV infusion resortium Instructure Slow V bolus, IV resortium Instructure Slow V bolus, IV infusion resortium Instructure Slow V bolus, IV infusion resortium Instructure IV bolus, IV infusion resortium Instructure IV bolus, IV infusion resortium Antidote for overdose Ciria caid IV bolus, IV infusion atzobotan solum Antineoplastic Solum cabonate IV bolus, IV infusion			Propylene glycol, ethyl	min
Metholexial sodiumAnstheticAnhydrous sodiumIV, IMarbonatearbonateInfusionIM, IV bolus, IVsuccinate SodiumAntibacterialManinolIV bolus, IV infusionMetronidazoleAntineoplasticLactose, Benzy alacholInfusionMitonycinAntineoplasticLactoseIV infusionPamidronate disodiumInhibition of boneMannitolIVPentostatinAntineoplasticMannitolIVPentolatinAntineoplasticMannitolIVPentolatinCong acting neuronuscular blocking agent-InfusionPipecuronium bromideLong acting neuronuscular blocking agent-IV bolus, IV infusionPralidoxime chlorideAntineoplastic-IV bolus, IV infusionStreptozocinAntineoplastic-IV bolus, IV infusionand Piperacillin sodiumAntineoplasticCitric acidIV bolus, IV infusionAntineoplasticCitric acidIV bolus, IV infusion-ThiobiteranAntineoplasticCitric acidIV bolus, IV infusionThiotepaAntineoplasticSodium citrate-ThiotepaAntinegraticSodium citrate-TioterstreamAntineoplasticTioterstreamAntineoplasticTioterstreamAntineoplasticTioterstreamAntineoplasticTioterstreamAntineoplasticTioterstreamAntineoplast			alcohol, sodium citrate	
carbonateBethyl predinsoleneHorme replacementSedium phosphate, Lactose, Benzyl alcoholM. IV bolus, IVsuccinate SodiumAntibacterialMannitolV bolus, IV infusionMetrondazoleAntibacterialMannitolW bolus, IV infusionPamidronate disodiumAntineoplasticLactoseNumPamidronate disodiumAntineoplasticMannitolSlow IV bolus, IVPentostatinAntineoplasticMannitolSlow IV bolus, IVPentostatinAntineoplasticMannitolMillPhentolamine mesylateLong acting acting agent	Methohexital sodium	Anesthetic	Anhydrous sodium	IV, IM
Methyl prednisoloneHormone replacementSodium phosphate, Lactose, Benzyl alcoholIM, V bolus, IVMetronidazoleAntibacterialMannitolIV bolus, IV infusionMitonycinAntineoplasticLactose, Benzyl alcoholIVPrainfornate disodiumInhibition of bone resorptionMannitolIVPentostatinAntineoplasticMannitolIVPhentolamine mesylateAntihypertensiveMannitolIM, IV bolus, IV infusionPipecuronium bromideLong acting neuronuscular blocking agent-IV bolus, IV infusionPralidoxime chlorideAntiacoplastic-IV bolusPralidoxime chlorideAntineoplastic-IV bolusRemiferanti It lefAntiacoplastic-IV bolusPralidoxime chlorideCancel for overdose onticholinesterase-IV bolus, IV infusionStreptozocinAntineoplasticCitric acidIV bolus, IV infusionAntineoplasticGlycineV infusionInfusionTripperacillin sodiumCombinationSodium citrateInfusionThiotepaAntineoplasticSodium citrateInfusionTipperacillin sodiumAntineoplasticSodium citrateIV infusionTipperacillin sodiumAntineoplasticMannitol, Titratic acidIN IV bolus, IV infusionTipperacillin sodiumAntineoplasticMannitol, Titratic acidIV infusionTipperacillin sodiumAntineoplasticMannitol, Titratic acidIV infusionTipperacillin sod			carbonate	
succinate SodiumLactose, Benzyl alcoholinfusionMetronidazoleAntineoplasticLactoseIV bolus, IV infusionMitomycinAntineoplasticLactoseIV infusionPamiltonate disodiumInhibition of boneMannitolWolus, IVPamiltonate disodiumAntineoplasticMannitolINPentoslatinAntineoplasticMannitolMunoPhentolamine mesylateAntihypertensiveMannitolMunoPipecuronium bromideLong acting neuromuscular-IV bolus, IVPipecuronium bromideLong acting neuromuscular-IV bolus, IV infusionPrafidoxime chlorideAntidofe for overdose due to anticholinesteraseIV bolus, IV infusionRemifentanil HelAnalgesicGilycineIV infusionAntibacterialEDTAIV bolus, IV infusionTazobactam sodiumAntibacterialSodium carbonateIV infusionAntipoplasticCitric acidIV bolus, IV infusionTazobactam sodiumAntipoplasticSodium carbonateIV infusionThiotpenal sodiumAntipoplasticSodium carbonateIV infusionTipotecanAntipoplasticImaroviscalIntravesicalTipotecanAntipoplasticImaroviscalIntravesicalTipotecanNatiscerialMannitolIMTipotecanPiezuronium bromideIntravesicalTipotecanPiezuronium bromideNinkisonTipotecanPiezuronium bromideNinkisonTipotecan <t< td=""><td>Methyl prednisolone</td><td>Hormone replacement</td><td>Sodium phosphate,</td><td>IM, IV bolus, IV</td></t<>	Methyl prednisolone	Hormone replacement	Sodium phosphate,	IM, IV bolus, IV
MetronidazoleAntibaceterialMannitolIV bolus, IV infusionMitomycinAntibaceterialMannitolIV infusionPamidronate disodiumInhibition of boneMannitolIVresorptionresorptionresorptionPentostatinAntibypertensiveMannitolMunitolPhentolamine mesylateAntihypertensiveMannitolIN, IV bolus, IV infusionPipecuronium bromideLong acting neuromuscular-IV bolusblocking agentIV bolus, IV infusionAntidote for overdose due to auticholinesterase-IV bolus, IV infusionStreptozocinAntineoplasticCitric acidIV bolus, IV infusionand Piperacillin sodiumCombinationGlycineIV infusionThiotepaAntineoplasticSodium carbonateIV infusionThiotepaAntineoplasticSodium carbonateIV infusionThiotepaAntineoplasticSodium carbonateIV infusionThiotepaAntineoplasticSodium carbonateIV infusionThiotepaAntineoplasticIV infusionInfusionTigecyclineAntineoplasticIV infusionInfusionTigecyclineAntineoplasticIV infusionIN infusionTigecyclineAntineoplasticIV infusionIN infusionTigecyclineAntineoplasticIV infusionIN infusionTigecyclineAntineoplasticIV infusionIN infusionTigecyclineAntineoplasticIV infusion<	succinate Sodium		Lactose, Benzyl alcohol	infusion
MitomycinAntineoplasticLactoseV infusionPamidronate disodiumInfusionWannitolIVPamidronate disodiumAntineoplasticMannitolSlow IV bolus, IV infusionPentostatinAntineoplasticMannitolMannitolPhentolamine mesylateAntihypertensiveMannitolMannitolPipecuronium bromideLong acting neuromuscular-IV bolus, IV infusionPipecuronium bromideLong acting neuromuscular-IV bolusPralidoxime chlorideAntidote for overdose auticholinesterase-IV bolus, IV infusionStreptozocinAntigoplasticGlycineIV infusionTazobactam sodiumAntibacterialGlycineIV infusionTazobactam sodiumAntibacterialSodium citrateIV infusionThiotepaAnticoplasticSodium citrateIntravesicalThiotepaAnticoplasticSodium citrateIntravesicalThiotepaAntibocrialMannitolIN infusionThiotepaAntibocrialMannitol, infusionIV bolus, IV infusionTiotepaAntibocrialMannitol, infusionIV infusionTiotepaAntibocrialMannitol, infusionIV infusionThiotepaAntibocrialMannitol, infusionIV infusionTiraterialToroIntravesicalIntravesicalTirotepaAntibocrialMannitol, infusionIV infusionTirotepaAntibocrialMannitol, infusionIV infusion <td>Metronidazole</td> <td>Antibacterial</td> <td>Mannitol</td> <td>IV bolus, IV infusion</td>	Metronidazole	Antibacterial	Mannitol	IV bolus, IV infusion
Pamiconate disodiumInhibition of bone recoprionManniolIVPentostatinAntincoplasticManniolSlow IV bolus, IV infusionPhentolamine mesylateAntihypertensiveManniolIM, IV bolus, IV infusionPipecuronium bromideLong acting neuromuscular blocking agent	Mitomycin	Antineoplastic	Lactose	IV infusion
Pentostatin Antineoplastic Antineopl	Pamidronate disodium	Inhibition of bone	Mannitol	IV
PentolamineAntineoplasticMannitolSlow IV bolus, IV infusionPhentolamine mesylateAntihypertensiveMannitolM, IV bolus, IV infusionPipecuronium bromideLong acting neuromuscular blocking agent-IV bolusPralidoxime chlorideAntidote for overdose due to anticholinesterase-IV bolus, IV infusionRemifentanil HclAnalgesicGlycineIV infusionAntiaceplasticCitric acidIV bolus, IV infusionStreptozocinAntineoplasticCitric acidIV bolus, IV infusionTazobactam sodiumAntineoplasticSodium citrateIntracavitary, Intracavitary, Intracavitary, Intracavitary, IntracesialThiopental sodiumShort acting anestheticSodium carbonateIV infusionThiotepaAntipsychoticMannitolMTigecyclineAntibacterialIV infusionTigecyclineAntibacterialIV infusionTrimetrexateTreatment of-IV infusionTrimetrexateTreatment of-IV infusionIgucuronatepneumoniaIVIV infusionVancomycin HClAntibacterialV infusionIV infusionVancomycin HClAntineoplastic-IV infusionVancomycin HClAntineoplasticIV infusionIV infusionVancomycin HClAntineoplasticIV infusionIV infusionVancomycin HClAntineoplasticIV infusionIV infusionVancomycin HClAntineoplasticIV infusion<		resorption		
Phentolamine mesylate Antihypertensive Mannitol infusion Pipecuronium bromide Long acting	Pentostatin	Antineoplastic	Mannitol	Slow IV bolus, IV
Phentolamine mesylate Antihyperensive Mannitol IM, IV bolus, IV infusion Pipecuronium bromide Long acting neuromuscular blocking agent Pralidoxime chloride Antiotof for overdose IV bolus, IV infusion due to anticholinesterase Remifentanil Hcl Analgesic Glycine IV infusion Streptozocin Antineoplastic Citric acid IV bolus, IV infusion Tazobactam sodium Antihacterial EDTA IV infusion and Piperacillin sodium combination Sodium citrate Thiopental sodium Antihacterial Thiothixene Hcl Antipsychotic Mannitol Tigecycline Antibacterial Tigecycline Antibacterial Tigecycline Antibacterial Topotecan Trimetrexate pneumonia Trimetrexate Treatment of - IV infusion Trimetrexate Mannitol Mannitol, Citric acid, IV infusion Trimetrexate Mannitol Mannitol, Citric acid, IV infusion Mannitol, Citric acid, IV infusion Vecuronium bromide Mannitol, Citric acid, IV infusion Vecuronium bromide Mannitol, Citric acid, IV infusion Vecuronium bromide Mannitol, Citric acid, IV infusion Mannitol, Citric acid, IV infusion Vecuronium bromide Mannitol, Citric acid, IV infusion Vecuronium bromide Muscle relaxant Mannitol, Citric acid, IV infusion Sodium phosphate monobasic, monohydrate Primetrexate for the trimetrexate Mannitol, Citric acid, Soliw IV over 2 min Sodium phosphate, monobasic, monohydrate Mannitol, Soliw IV over 2 min Sodium phosphate, monobasic, monohydrate Primetrexate IV Infusion Primetrexate IV Infusion Primetrexate Antibozite Mannitol, Citric acid, Soliw IV over 2 min Sodium phosphate, monobasic, monohydrate Primetrexate IV Infusion Primetrexate IV Infusion Primetrexate IV Infusion Primetrexate IV Infusion Primetrexate IV Infusion Primetrexate IV IN				infusion
Pipecuronium bromideLong acting neuromuscular blocking agent-IV bolusPralidoxime chlorideAntidote for overdose due to anticholinesterase-IV bolus, IV infusionRemifentanil HclAnalgesicGlycineIV bolus, IV infusionStreptozocinAntineoplasticCitric acidIV bolus, IV infusionTazobactam sodiumAntibacterialEDTAIV infusionand Piperacillin sodiumCombinationSodium citrateIntravesicalThiopental sodiumAntipoplasticSodium carbonateIV infusionThiotepaAntineoplasticSodium carbonateIV infusionThiotepaAntineoplasticSodium carbonateIntravesicalThiotepaAntineoplasticSodium carbonateIN Nolus, IV infusionThiotepaAntineoplasticIntravesicalIntravesicalThiotepaAntibacterialMannitolIM Nolus, IVTreatment of-InfusionTrateria caidIntravesicalInfusionVancomycin HClAntibotic-InfusionVancomycin HClAntibiotic-InfusionVancomycin HClAntibiotic-Vi fusionVandariar sodiumMuscle relaxantMannitol, Citric acid, Sodium phosphate dibasicVi bolus, IV infusionVinblastin sulfateAntineoplasticMannitol, Citric acid, Sodium reloride, Sodium phosphate, monobasic, monohydrateSodiur Phosphate, Sodium	Phentolamine mesylate	Antihypertensive	Mannitol	IM, IV bolus, IV
Pipecuronium bromideLong acting neuromuscular blocking agent-IV bolusPralidoxime chlorideAntidote for overdose due to anticholinesterase-IV bolus, IV infusionRemifentanil HelAnalgesicGlycineIV infusionStreptozocinAntineoplasticCitric acidIV bolus, IV infusionTazobactam sodiumAntibacterialEDTAIV infusionTazobactam sodiumAntibacterialSodium citrateIV infusionThiopental sodiumShort acting anestheticSodium carbonateIV infusionThiotepaAntineoplasticSodium carbonateIV infusionThiotepaAntineoplasticSodium carbonateIN infusionThiotepaAntineoplasticImanitolImanitolThiotepaAntibacterialImanitolImanitolTigecyclineAntibacterialImanitolImanitolTigecyclineAntineoplasticImanitol,IV infusionTigecyclineAntibacterialImanitol,IV infusionTigecyclineAntibacterialImanitol,IV infusionTigecyclineAntibacterialImanitol,IV infusionTigecyclineAntibacterialImanitol,IV infusionTigecyclineAntibacterialImanitol,IV infusionTigecyclineAntibacterialImanitol,IV infusionTigecyclineAntibacterialImanitol,IV infusionTopotecanPieumoniaImanitol,IV infusionVancomycin HCIAntibotic <t< td=""><td></td><td></td><td></td><td>infusion</td></t<>				infusion
Pralidoxine chlorideneuromuscular blocking agentPralidoxine chlorideAntidote for overdose due to anticholinesterase-IV bolus, IV infusionRemifentanil HclAnalgesicGlycineIV infusionStreptozocinAntineoplasticCitric acidIV bolus, IV infusionTazobactam sodiumAntibacterialEDTAIV infusionand Piperacillin sodiumCombinationSodium citrateIV infusionThiopental sodiumShort acting anestheticSodium carbonateIV infusionThiotepaAntineoplasticSodium carbonateIV bolus, IN fusionThiotepaAntineoplasticSodium carbonateIV bolus, Intracavitary, IntravesicalThiotepaAntipsychoticMannitolIMTigecyclineAntiacetrialIMIN infusionTrimetrexateTreatment of-IV infusionTrimetrexateTreatment of-IV infusionglucuronateMuscle relaxantMannitol, Citrie acid, Sodium phosphate abasicIV infusionVinblastine sulfateAntineoplasticIMIV infusionVinblastine sulfateAntineoplastic-IV infusionVinblastine sulfateAntineoplasticSodium phosphate adasicIV infusionVinblastine sulfateAntineoplasticIV infusionSolium phosphate, monobasic, monobydrateIV oolusVinblastine sulfateAntineoplasticSolium phosphate, monobasic, monobydrateIV oolus	Pipecuronium bromide	Long acting	-	IV bolus
Pralidoxime chloride Antidote for overdose - IV bolus, IV infusion Pralidoxime chloride Antidote for overdose - IV bolus, IV infusion Remifentanil Hcl Analgesic Glycine IV infusion Streptozocin Antineoplastic Citric acid IV bolus, IV infusion Tazobactam sodium Antibacterial EDTA IV infusion Thiopental sodium Combination Sodium citrate IV infusion Thiopental sodium Short acting anesthetic Sodium carbonate IV bolus, Intracevitary, Intracevitary, Intravesical Thiotepa Antineoplastic Mannitol Mannitol IM Ticarcillin disodium Antibacterial IV bolus, IV infusion Intravesical Trimetrexate Antineoplastic Mannitol, Nacion IV infusion Trimetrexate pneumonia IV infusion IV infusion Vecuronium bromide Muscle relaxant Mannitol, Citric acid, IV infusion IV infusion Vecuronium bromide Anticogulant Sodium phosphate dibasic IV infusion IV infusion Vinblastine sul		neuromuscular		
Praildoxime chloride Antidoe for overdose due to due to anticholinesterase - N bolus, IV infusion Remifentanil Hel Analgesic Glycine IV infusion Streptozocin Antineoplastic Citric acid IV bolus, IV infusion Tazobactam sodium Antineoplastic EDTA IV infusion and Piperacillin sodium combination Sodium citrate IV infusion Thiopental sodium Short acting anesthetic Sodium carbonate IV infusion Thiopental sodium Short acting anesthetic Sodium carbonate IV bolus, Intracevitary, Intravesical Thiotepa Antipsychotic Mannitol IM Intravesical Tricarcillin disodium Antibacterial IM, IV bolus, IV infusion Intravesical Tigecycline Antineoplastic Mannitol, IV infusion Intravesical Trimetrexate Treatment of - IV infusion Quecuronate pneumonia IV infusion IV infusion Vancomycin HCl Antibotic - IV infusion Vecuronium bromide Muscle relaxant Mannitol, Citric acid, Sodium phosphate, monobasic, monohydrate IV bolus <tr< td=""><td>~</td><td>blocking agent</td><td></td><td></td></tr<>	~	blocking agent		
due to anticholinesteraseGlycineIV infusionRemifentanil HclAnalgesicGlycineIV infusionStreptozocinAntineoplasticCitric acidIV bolus, IV infusionTazobactam sodiumAntibacterialEDTAIV infusionand Piperacillin sodiumcombinationSodium citrateIV infusionThiopental sodiumShort acting anestheticSodium carbonateIV infusionThiotepaAntipsychoticMannitolIN infusionTriacrelin disodiumAntipsychoticMannitolIMTigecyclineAntibacterialIV infusionTigecyclineAntineoplasticMannitol,IV infusionTrimetrexatepneumoniaIV infusionglucuronatepneumoniaIV infusionVecuronium bromideAntibotic-IV infusionVecuronium bromideAntibotic-IV infusionVancomycin HClAntineoplasticIV infusionIV infusionVancomycin HClAntineoplastic-IV infusionVancomycin HClAntineoplastic-IV infusionVancomycin HClAntineoplastic-IV infusionVantariin sodiumAntineoplastic-IV infusionVancomycin HClAntineoplastic-IV infusionVancomycin HClAntineoplastic-IV infusionVancomycin HClAntineoplastic-IV infusionVancomycin HClAntineoplastic-IV infusionWarfarin sodiumAnticogaulant	Pralidoxime chloride	Antidote for overdose	-	IV bolus, IV infusion
AntipolaticGlycineIV infusionStreptozocinAntipoplasticCitric acidIV bolus, IV infusionTazobactam sodiumAntibacterialEDTAIV infusionand Piperacillin sodiumcombinationSodium citrateIV infusionThiopental sodiumShort acting anestheticSodium carbonateIV infusionThiotepaAntineoplasticSodium carbonateIV infusionThiotepaAntipsychotic-IV bolus, Intracavitary, IntravesicalThiothixene HclAntipsychoticMannitolMTigecyclineAntibacterialIV infusionTigecyclineAntibacterialIV infusionTrimetrexatepneumonia-IV infusionglucuronatepneumonia-IV infusionVancomycin HClAntiboite-IV infusionVecuronium bromideMuscle relaxantMannitol, Citric acid, Sodium phosphate dibasicIV infusionVinblastine sulfateAntineoplastic-IV infusionVinblastine sulfateAntineoplastic-IV infusionVinblastine sulfateAntineoplastic-IV infusionVinblastine sulfateAntineoplastic-IV infusionWarfarin sodiumAntineoplastic-IV infusionVinblastine sulfateAntineoplastic-IV infusionVinblastine sulfateAntineoplastic-IV bolusWarfarin sodiumAntineoplastic-IV bolusVinblastine sulfateAntineoplastic- </td <td></td> <td>due to</td> <td></td> <td></td>		due to		
Reminentanti FielAnalgesicGlycheIV infusionStreptozocinAntineoplasticCitric acidIV bolus, IV infusionand Piperacillin sodiumcombinationSodium citrateIV infusionThiopental sodiumShort acting anestheticSodium carbonateIV infusionThiopental sodiumShort acting anestheticSodium carbonateIV infusionThiotepaAntineoplastic-IV bolus, INtracavitary, IntravesicalThiothixene HelAntipsychoticMannitolIMTicarcillin disodiumAntibacterialIV infusionTigecyclineAntineoplasticIV infusionTopotecanAntineoplasticIV infusionTrimetrexateTreatment of-plucuronatepneumoniaIV infusionVancomycin HClAntibolic-IV infusionVancomycin HClAntineoplasticIV infusionVinblastine sulfateManitol, Citric acid, Sodium phosphate dibasicIV bolus, IV infusionWarfarin sodiumAntineoplasticIV infusionVinblastine sulfateAntineoplasticIV bolus, IV infusionWarfarin sodiumAntineoplasticIV bolus, IV infusionVinblastine sulfateAntineoplastic-Vinblastine sulfateAntineoplasticIV bolusVinblastine sulfateAntineoplasticIV bolusVinblastine sulfateAntineoplasticIV bolusVinblastine sulfateAntineoplasticIV bolusVinblastine sulfateAntineoplasticIV bolu	D (C (1111)	anticholinesterase		
StreptozecinAntineoplasticCitri acidI/V bolus, I/V infusionTazobactam sodiumAntibacterialEDTAIV infusionand Piperacillin sodiumcombinationSodium citrateIV infusionThiopental sodiumShort acting anestheticSodium carbonateIV infusionThiotepaAntineoplastic-IV bolus, Intracavitary, IntravesicalThiothixene HclAntipsychoticMannitolIMTicarcillin disodiumAntibacterialIV infusionTigecyclineAntibacterialIV infusionTopotecanAntineoplasticMannitol, IntravesicalIV infusionTrimetrexateTreatment of pouronial-IV infusionglucuronatepneumonia-IV infusionVancomycin HClAntibotic-IV infusionVecuronium bromideMuscle relaxantMannitol, Citric acid, Sodium phosphate dibasicIV bolusVinblastine sulfateAntineoplasticIV antiol, Sodium chloride, Sodium phosphate, monobasic, monohydrateIV bolusVinblastine sulfateAnticoagulantMannitol, Sodium chloride, Sodium phosphate, monobasic, monohydrateSlow IV over 2 min	Remitentanii Hei	Analgesic	Glycine	
Tazloactain sodium Antibacterial EDIA IV mitusion and Piperacillin sodium combination Sodium citrate IV infusion Thiopental sodium Short acting anesthetic Sodium carbonate IV infusion Thiotepa Antineoplastic - IV bolus, Intracavitary, Intravesical Thiothixene Hcl Antipsychotic Mannitol IM Ticarcillin disodium Antibacterial IM, IV bolus, IV infusion IN Tigecycline Antibacterial IV infusion IV infusion Topotecan Antineoplastic Mannitol, Tartaric acid IV infusion Trimetrexate Treatment of pneumonia - IV infusion Vancomycin HCl Antibiotic - IV infusion Vecuronium bromide Muscle relaxant Mannitol, Citric acid, Sodium phosphate dibasic IV infusion Vinblastine sulfate Antineoplastic Mannitol, Sodium chloride, Sodium phosphate, monobasic, monohydrate Slow IV over 2 min Sodium phosphate, monobasic, monohydrate	Streptozocin	Antineoplastic		IV bolus, IV infusion
and riperaction solution Solution circles Thiopental sodium Short acting anesthetic Sodium carbonate IV infusion Thiotepa Antineoplastic - IV bolus, Intracavitary, Intravesical Thiothixene Hel Antipsychotic Mannitol IM Ticarcillin disodium Antibacterial IM, IV bolus, IV infusion Tigecycline Antineoplastic Mannitol, IV infusion Topotecan Antineoplastic Mannitol, IV infusion Trimetrexate Treatment of - IV infusion glucuronate pneumonia Vancomycin HCl Antibiotic - Vancomycin HCl Antineoplastic Mannitol, Citric acid, Sodium phosphate dibasic IV bolus, IV infusion Vinblastine sulfate Antineoplastic - IV infusion Vinblastine sulfate Antineoplastic IV anonobysphate, monobysphate, monobydrate Slow IV over 2 min Sodium phosphate, monobydrate Solutin choride, Solium phosphate, monobydrate Slow IV over 2 min	and Dinerosillin as dium	Antibacterial	EDIA Sodium citrate	IV Infusion
Thiopental sodiumShort acting anestheticSodium carbonateIV infusionThiotepaAntineoplastic-IV bolus, Intracavitary, IntravesicalThiothixene HclAntipsychoticMannitolIMTicarcillin disodiumAntibacterialIM, IV bolus, IV infusionTigecyclineAntibacterialIV infusionTopotecanAntineoplasticMannitol, Tartaric acidIV infusionTrimetrexateTreatment of pneumonia-IV infusionglucuronatepneumoniaIV infusionVecuronium bromideMuscle relaxant-IV infusionVinblastine sulfateAntineoplastic-IV infusionVinblastine sulfateAntineoplastic-IV infusionVinfusion-IV infusion-Vinblastine sulfateAntineoplastic-IV infusionVinblastine sulfateAntineoplasticIV infusion-Vinblastine sulfateAnticoagulantMannitol, Citric acid, Sodium phosphate, monobasic, monohydrateSlow IV over 2 minSodium phosphate, monobasic, monohydrateSolium phosphate, monobasic, monohydrateSlow IV over 2 min	and Piperacinin sodium	combination	Socium cirrate	
ThiotepaAntineoplastic-IV bolus, Intracavitary, IntravesicalThiothixene HclAntipsychoticMannitolIMTicarcillin disodiumAntibacterialIM, IV bolus, IV infusionTigecyclineAntibacterialVinfusionTigecyclineAntineoplasticMannitol, Tartaric acidIV infusionTrimetrexateTreatment of pneumonia-IV infusionglucuronatepneumonia-IV infusionVecuronium bromideMuscle relaxantMannitol, Citic acid, dibasicIV infusionVinfusion sulfateAntineoplastic-IV infusionVinfusion HClAntibiotic-IV infusionVecuronium bromideMuscle relaxantMannitol, Citic acid, dibasicIV bolus, IV infusionVinfusion sulfateAntineoplasticIV bolusIV infusionVinfusion sulfateAntineoplasticIV bolusIV infusionVinfusion bromideAntinoplasticIV bolusIV infusionVinfusion bromideMuscle relaxantMannitol, Citic acid, dibasicIV bolus, IV infusionVinfusion sulfateAntineoplasticIV bolusIV over 2 minSodium phosphate, monobasic, monohydrateSolow IV over 2 minSoliw IV over 2 minVinfusion to the tot be totSoliw IV over 2 minSoliw IV over 2 min	Thiopental sodium	Short acting anesthetic	Sodium carbonate	IV infusion
Thiothixene HclAntipsychoticMannitolIntravesicalThiothixene HclAntipsychoticMannitolIMTicarcillin disodiumAntibacterialIM, IV bolus, IVTigecyclineAntibacterialIV infusionTigecyclineAntineoplasticMannitol,IV infusionTopotecanAntineoplasticMannitol,IV infusionTrimetrexateTreatment ofIV infusionglucuronatepneumoniaIV infusionVancomycin HClAntibiotic-IV infusionVecuronium bromideMuscle relaxantMannitol, Citric acid, Sodium phosphate dibasicIV bolus, IV infusionVinblastine sulfateAntineoplasticIV bolusIV infusionWarfarin sodiumAnticoagulantMannitol, Sodium chloride, Sodium phosphate, monobasic, monohydrateSlow IV over 2 minSolicur on backSolicur on backSlow IV over 2 min	Thiotepa	Antineoplastic	-	IV bolus, Intracavitary,
Thiothixene Hel Antipsychotic Mannitol IM Ticarcillin disodium Antibacterial IM, IV bolus, IV infusion Tigecycline Antibacterial IV infusion Tigecycline Antibacterial IV infusion Topotecan Antineoplastic Mannitol, Infusion Trimetrexate Treatment of Treatric acid glucuronate pneumonia IV infusion Vaccomycin HCl Antibotic IV infusion Vecuronium bromide Muscle relaxant Mannitol, Citric acid, Sodium phosphate dibasic IV bolus, IV infusion Vinblastine sulfate Antieoplastic IV bolus IV infusion Warfarin sodium Anticoagulant Mannitol, Citric acid, Sodium chloride, Sodium phosphate, monobydrate IV over 2 min Out work to the bet bet bet bet bet bet bet bet bet be		-		Intravesical
Ticarcillin disodiumAntibacterialIM, IV bolus, IV infusionTigecyclineAntibacterialIV infusionTopotecanAntineoplasticMannitol, Tartaric acidIV infusionTrimetrexateTreatment of pneumonia-IV infusionglucuronatepneumoniaIV infusionVancomycin HClAntibiotic-IV infusionVecuronium bromideMuscle relaxantMannitol, Citric acid, Sodium phosphate dibasicIV bolus, IV infusionVinblastine sulfateAntineoplasticIV bolusIV infusionWarfarin sodiumAnticoagulantMannitol, Sodium chloride, Sodium phosphate, monobasic, monohydrateSlow IV over 2 min	Thiothixene Hcl	Antipsychotic	Mannitol	IM
TigecyclineAntibacterialInfusionTopotecanAntineoplasticMannitol, Tartaric acidIV infusionTrimetrexateTreatment of-IV infusionglucuronatepneumoniaIV infusionVancomycin HClAntibiotic-IV infusionVecuronium bromideMuscle relaxantMannitol, Citric acid, Sodium phosphate dibasicIV bolus, IV infusionVinblastine sulfateAntineoplasticIV bolusWarfarin sodiumAnticoagulantMannitol, Sodium chloride, Sodium phosphate, monobasic, monohydrateSlow IV over 2 min	Ticarcillin disodium	Antibacterial		IM, IV bolus, IV
TigecyclineAntibacterialIV infusionTopotecanAntineoplasticMannitol, Tartaric acidIV infusionTrimetrexateTreatment of-IV infusionglucuronatepneumonia-IV infusionVancomycin HClAntibiotic-IV infusionVecuronium bromideMuscle relaxantMannitol, Citric acid, Sodium phosphate dibasicIV bolus, IV infusionVinblastine sulfateAntineoplasticIV bolusWarfarin sodiumAnticoagulantMannitol, Sodium chloride, Sodium phosphate, monobasic, monohydrateSlow IV over 2 min				infusion
Topotecan Antineoplastic Mannitol, Tartaric acid IV infusion Trimetrexate Treatment of - IV infusion glucuronate pneumonia IV infusion Vancomycin HCl Antibiotic - IV infusion Vecuronium bromide Muscle relaxant Mannitol, Citric acid, Sodium phosphate IV bolus, IV infusion Vinblastine sulfate Antineoplastic IV bolus IV bolus Warfarin sodium Anticoagulant Mannitol, Sodium chloride, Sodium phosphate, monobasic, monohydrate Slow IV over 2 min	Tigecycline	Antibacterial		IV infusion
Trimetrexate Treatment of - IV infusion glucuronate pneumonia - Vancomycin HCl Antibiotic - IV infusion Vecuronium bromide Muscle relaxant Mannitol, Citric acid, Sodium phosphate dibasic IV bolus, IV infusion Vinblastine sulfate Antineoplastic IV bolus Warfarin sodium Anticoagulant Mannitol, Sodium chloride, sodium phosphate, monobasic, monohydrate Slow IV over 2 min	Topotecan	Antineoplastic	Mannitol,	IV infusion
Trimetrexate Treatment of - IV infusion glucuronate pneumonia - IV infusion Vancomycin HCl Antibiotic - IV infusion Vecuronium bromide Muscle relaxant Mannitol, Citric acid, Sodium phosphate dibasic IV bolus, IV infusion Vinblastine sulfate Antineoplastic IV bolus Warfarin sodium Anticoagulant Mannitol, Sodium chloride, Sodium phosphate, monobasic, monohydrate Slow IV over 2 min			Tartaric acid	
glucuronate pneumonia Vancomycin HCl Antibiotic - IV infusion Vecuronium bromide Muscle relaxant Mannitol, Citric acid, Sodium phosphate dibasic IV bolus, IV infusion Vinblastine sulfate Antineoplastic IV bolus IV bolus Warfarin sodium Anticoagulant Mannitol, Sodium chloride, Sodium phosphate, monobasic, monohydrate Slow IV over 2 min	Trimetrexate	Treatment of	-	IV infusion
Vancomycin HCl Antibiotic - IV infusion Vecuronium bromide Muscle relaxant Mannitol, Citric acid, Sodium phosphate dibasic IV bolus, IV infusion Vinblastine sulfate Antineoplastic IV bolus Warfarin sodium Anticoagulant Mannitol, Sodium chloride, Sodium phosphate, monobasic, monohydrate Slow IV over 2 min	glucuronate	pneumonia		
Vecuronium bromide Muscle relaxant Mannitol, Citric acid, IV bolus, IV infusion Sodium phosphate dibasic IV bolus Warfarin sodium Anticoagulant Mannitol, Sodium chloride, Slow IV over 2 min Sodium phosphate, monobasic, monohydrate	Vancomycin HCl	Antibiotic	-	IV infusion
Sodium phosphate dibasic Vinblastine sulfate Antineoplastic IV bolus Warfarin sodium Anticoagulant Mannitol, Sodium chloride, Slow IV over 2 min Sodium phosphate, monobasic, monohydrate Solive here here	Vecuronium bromide	Muscle relaxant	Mannitol, Citric acid,	IV bolus, IV infusion
Vinblastine sulfate Antineoplastic IV bolus Warfarin sodium Anticoagulant Mannitol, Sodium chloride, Sodium phosphate, monobasic, monohydrate Slow IV over 2 min			Sodium phosphate	
VINDIASURE Antineoplastic IV bolus Warfarin sodium Anticoagulant Mannitol, Sodium chloride, Sodium phosphate, monobasic, monohydrate Slow IV over 2 min			dibasic	1771
warrarin sodium Anticoagulant Mannitol, Sodium chloride, Slow IV over 2 min Sodium phosphate, monobasic, monohydrate	Vinblastine sulfate	Antineoplastic		IV bolus
Sodium phosphate, monobasic, monohydrate	wartarin sodium	Anticoagulant	Mannitol, Sodium chloride,	Slow IV over 2 min
nunobasic, mononydrate			Sourium prosprate,	
			Sodium phoenhoto	
dibasie Hantabudrata			dibasic Heptahydrate	

3.5. Excipients in Pharmaceutical Suspension

Parenteral suspension is useful dosage form for

administering insoluble or poorly soluble drugs. The larger surface area of disperse drug may help to ensure a high degree of availability for absorption. Parenteral suspension provides more prolonged release from the injection site than a comparable solution. Typical excipients used in Parenteral suspensions include following:

Flocculating / suspending agents. Wetting agents. Solvent systems Preservatives Antioxidants Chelating agents Buffering agents Tonicity adjusting agents

Tahle	4	Antimicrobial	agents
IUDIC	т.	Ammicrooiui	uzems.

Excipients	range	Example
Benzalkonium	0.02 % w/v	Celestone Soluspan
Chloride		
Benzethonium	0.01%	Benadryl
Chloride		
Panzul alaahal	0.75.5.9/	Dimenhydrinate
Benzyi alconor	0.75-570	Injection,
		USP
Chlorobutanol	0.25-0.5 %	Codine phosphate
m-Cresol	0.1-0.315%	Humalog
Myristyl gamma-	0.0195-0.169 %	Depo-Provera
picolinium		
Chloride		
Paraben methyl	0.05-0.18%	Inapsine
Paraben propyl	0.005-0.1%	Xylocaine
Phenol	0.15-0.5%	Calcimar
2-Penoxyethanol	0.50%	Havrix
Phenyl mercuric	0.001%	Antivenin
nitrate		
Thimerosal	0.003-0.012%	Atgam

3.6. Flocculating / Suspending Agents

The controlled flocculation approach uses a flocculating agents to from loosely bound aggregate or flocs in a controlled manner that settles rapidly but redisperses easily upon agitation. An appropriate amount or flocculating agent is added that result in maximum sedimentation volume & prevents cake formation. Electrolytes, surfactant and hydrophilic colloids have been typically used as flocculating agents. Electrolytes & surfactants reduce the electrical forces of repulsion between particles & allow the flocs to form, which in turn is influenced by the surface charge on the particles.

E.g. Electrolytes used in Parenteral Suspensions.

- Potassium/sodium chloride
- Potassium/sodium citrate
- Potassium/sodium acetate

The surface charge of the system can be measured by the zeta potential. The zeta potential must be controlled so as to lie within a range (generally less than 25 mV) to obtain a flocculated, noncaking suspension with maximum sedimentation. Hydrophilic colloids (generally negatively charged) not only affect the repulsive force but also provide mechanical barrier to the particles. For e.g. a 25% PVP solution is used in combination with polysorbate 80 (2%) acts as a stabilizer to provide a stable injectable 30% aqueous powder suspension.

Some viscosity building agents used in formulation of

injectable suspension are: Sodium carboxymethyl cellulose Acacia Gelatin Methyl cellulose Polyvinyl pyrrolidone.

Table	: 5.	Chel	lating	agents.
-------	------	------	--------	---------

Excipients	range
Calcium disodium	0.01-0.1%
EDTA*	0.01-0.05%
Disodium EDTA	0.01-0.11%
Sodium EDTA	0.20%
Calcium	2.84%
Versetamide Na	
Calteridol	0.023%
DTPA**	0.04-1.2%

*EDTA = Ethylenediaminetetra acetic acid

**DTPA = Diethylenetriaminepenta acetic acid

Excipients	range
Sodium acetate	0.01%
Sodium phosphate, monobasic	0.14%
Sodium phosphate	0.50/
monobasic, dihydrate	0.370
Sodium chloride	45%
Mannitol	5%

3.7. Wetting Agents

Various nonionic surfactants and non-aqueous solvents like glycerin, alcohol & propylene glycol are types of wetting agents commonly used in injectable suspensions. Wetting agents reduce the contact angle between the surface of the particle & the wetting liquid to obtain maximum wetting efficiency, surfactants with hydrophilic lipophilic balance (HLB) value in the range of 7to 9 should be selected. The usual concentration of surfactants varies from 0.05% to 0.5% depending on the solid contents of the suspension. Care should be taken in terms of the amount used, excessive amounts may cause foaming or caking or provide an undesirable taste/odor to the product.

3.8. Surfactants (Wetting Agent)

Lecithin, Polysorbate 20, Polysorbate 80, Pluronic F-68, Sorbitan trioleate (span 85) are used, as surfactants in injectable suspensions for e.g. in the preparation of a nonaqueous suspension of Cefazolin sodium in peanut oil, addition of polysorbate 80 at concentration greater than 0.17% resulted in deflocculated suspension which was difficult to redisperse. Microscopic examination revealed extensive agglomeration and crystal growth of cefazolin sodium in the presence of polysorbate 80.

3.9. Solvent System

Solvent systems used in parenteral suspension are classified as either aqueous or non-aqueous vehicles. Choice of a typical solvent system depends on solubility, stability &

desired release characteristics of the drug. Non-aqueous vehicles include both water miscible and water immiscible vehicles. Water for injection is generally the preferred solvent system. However, non-aqueous water miscible agents are used as co-solvents with water for injection to promote the solubility & stability in parenteral preparation. Examples of water miscible non-aqueous vehicles include ethanol,

glycerin, propylene glycol and n-lactamide. The use of water miscible co-solvents can lead to undesirable side effect for e.g. intramuscular injection of propylene glycol-water, ethyl alcohol-water & polyethylene glycol (PEG) 400 water mixtures was found to cause muscle damage as measured by in vitro release of creatinine kinase from isolated rat skeletal muscle.

Table 7. Pharmaceutical Excipients use and route of Administration.

Excipients	uses	Administration
Aluminum chloride	Potentiating agent	sc, im
Aluminum hydrox-	Adsorbent	sc, im
ide		
Aminoethyl sulfonic	Buffer, isotonicity, stabilizer, vehicle	iv, im
acid		
Ammonium acetate	pH adjusting agent	im
Anhydrous stan-	Reducing agent	iv
nous chloride		
L-Arginine	Buffer, stabilizer, solubilizer	iv, im, sc
Asepsis sodium	Stabilizer	iv
bicarbonate		
Butylhydroxyanisol	Antioxidant, stabilizer	iv
m-Cresol	Preservative	iv, im, sc, ic
L-Cysteine	Stabilizer	iv
Cysteine hydrochlo-	Antioxidant, stabilizer	iv, im
ride		
Dichlorodiluor-	Propellant	iv
omethane		
Diethanolamine	Buffer, solubilizer,	iv
	stabilizer	
Diethylenetri-	Stabilizer	iv
aminepentaacetic		
acid		
Ferric chloride	Stabilizer	iv
Highly purified yolk	Emulsifier	iv
lecithin		
Human serum	Preservative, stabilizer	iv, im, sc
albumin		
Hydrolyzed gelatin	Stabilizer	SC
Inositol	Stabilizer, vehicle	iv, im
Lidocaine hydro-	Soothing agent	im
chloride		
D,L-Methionine	Stabilizer	im, sc
Monobasic sodium	Buffer, Isotonicity,	iv, im, sc
phosphate	adjust pH	
Oleic acid	Dispersing agent,	iv
	solvent	
Phenol red	Coloring agent	SC

3.10. Tonicity Agents

Isotonicity of the Parenteral suspension for subcutaneous or intramuscular administration is desired to prevent pain; irritation and tissue damage at the site of administration, the aqueous solution of tonicity agents used in Parenteral suspensions include dextrose & various electrolytes.

3.11. Preservatives

Antimicrobial agents are required for parenteral products that are intended for multiple dosing, in order to protect the product from accidental microbial contamination during clinical usage & maintain sterility. Some typical preservative used in parenteral suspensions and their commonly used concentrations are as follows.

Benzyl alcohol (0.9% to 1.5%) Methylparaben (0.18%to0.2%) Propylparaben (0.02%) Benzalkonium chloride (0.01% to 0.02%) Thiomersal (0.001% to 0.01%)

Benzalkonium chloride is used in ophthalmic dosage forms & not in injectable dosage forms.

Propyl and methyl parabens are referred to chemically as Propyl and methyl esters of p-hydroxy benzoic acids. Because of the inherent chemically reactive nature of preservatives, stability & compatibility problems need to be evaluated for their usage in the formulation.

Compound	Typical Concentration			
	(%w/w)			
Ascorbic acid	0.02-0.1			
Sodium bisulfite	0.1-0.15			
Sodium meta bisulfite	0.1-0.15			
Sodium formaldehyde sulfoxylate	0.1-0.15			
Thiourea	0.005			
Table 9. Antioxidants (oil soluble).				
Ascorbic acid ester	0.01-0.15			
Butylated hydroxy toluene	0.005-0.02			
Tocopherols	0.05-0.075			

Table 8. Antioxidants/chelating agents.

4. Criteria for the Selection of Excipients

The following key points should be considered in selecting excipients for parenteral products:

Influence of excipients on the overall quality, stability, and effectiveness of drug product. Compatibility of excipient with drug and the packaging system. Compatibility of excipients with the manufacturing process, for example, preservatives may be absorbed by rubber tubes or liters, acetate buffers will be lost during lyophilization process etc. The amount or percentage of excipients that can be added to the drug product.

Route of administration. The USP, Ph. Eur, BP do not allow preservatives to be present in injections intended to come in contact with brain tissues or CSF. Thus intracisternal, epidural, and intradural injections should be preservative free. Also, it is preferred that a drug product to be administered via intravenous (IV) route be free of particulate matter. However, if the size of the particle is well controlled, like in fat emulsion or colloidal albumin or amphotericin B dispersion, it can be administered by IV infusion. Table 7 list excipients and their use along with route of administration Dose volume. All LVPs and those SVPs where the single dose injection volume can be greater than 15 ml are required by the EP/BP to be preservative free (unless justified). The USP recommends that special care be observed in the choice and the use of added substances in preparations for injections that are administered in volumes exceeding 5 ml.

Whether the product is intended for single or multiple dose use. According to USP, single dose injections should be free of preservative. The FDA takes the position that even though a single dose injection may have to be aseptically processed, the manufacturer should not use a preservative to prevent microbial growth. European agencies have taken a more lenient attitude on this subject. The length or duration of time that the drug product will be used once the multidose injection is opened. Several new excipients, such as cyclodextrins, are being evaluated to improve solubility or stability of parenteral drugs. Currently, there are two FDAapproved parenteral products that utilize alpha and gamma cyclodextrins. Beta-cyclodextrin is unsuitable for Parenteral administration because it causes necrosis of the proximal kidney tubules upon intravenous and subcutaneous administration.

Biodegradable polymeric materials (polylactic acid, polyglycolic acid, and other poly-alpha-hydroxy acids) have been used as medical devices and as biodegradable sutures since the 1960s. Currently, the FDA has approved for marketing only devices made from homopolymers or copolymers of glycolide, lactide, caprolactone, p-dioxanone, and trimethylene carbonate.

5. Conclusion

Several new excipients, such as cyclodextrin, are being evaluated to improve solubility or stability of parenteral drugs. Currently, there are two FDA-approved parenteral products that utilize alpha and gamma cyclodextrin. Betacyclodextrin is unsuitable for parenteral administration because it causes necrosis of the proximal kidney tubules upon intravenous administration. Biodegradable polymeric materials (polylactic acid, polyglycolic acid, and other polyalpha-hydroxy acids) have been used as medical devices and as biodegradable sutures since the 1960s. Injectable formulations are used with intravenous, subcutaneous, intramuscular, and intra-articular administration. The drug is stored in liquid or if unstable, lyophilized form. These include solubilizers, stabilizers, buffers, tonicity modifiers, bulking agents, viscosity enhancers/reducers, surfactants, chelating agents, and adjuvants. In this review we discus all excipients and there percentage.

References

- Robertson MI. Regulatory issues with excipients. Int. J. Pharm. 1999; 187: 273–276.
- [2] Nema S, Brendel RJ. Excipients and their role in approved injectable products: current usage and future directions. PDA J Pharm Sci Technol. 2011; 65(3):287-332.
- [3] BP. Parenteral Preparations. In British Pharmacopoeia, Stationary Ofice London. 1999; Vol. II: 1575.
- [4] EP. Parenteral Preparations. European Pharmacopoeia. Council of Europe, Strasbourg. 2009; 6th edition: 1765.
- [5] Jennings TA. Effect of formulation on lyophilization, part 1. IVD Technology Magazine, 1997.
- [6] Pikal MJ. Freeze-drying of proteins. Part II: Formulation selection. BioPharm. 1990; 3:26-30.
- [7] Crowe JH, Hoekstra FA, Crowe LM. Anhydrobiosis, Annu. Rev. Physiol. 1992; 54: 579–599.
- [8] Crowe LM, Reid DS, Crowe JH. Is trehalose special for preserving dry materials? Biophys. J. 1996; 71: 2087–2093

- [9] Townsend MW, Deluca MEPP. Use of Lyoprotectants in the Freeze-Drying of a Model Protein, Ribonuclease A. PDA Journal of Pharmaceutical Science and Technology. 1988; 42 (6): 190-199.
- [10] Richard LR, Krishnan, SK, William JC. Development of Stable Lyophilized Protein Drug Products. Current Pharmaceutical Biotechnology. 2012; 13(3): 471-496
- [11] Frank KBA. Understanding Lyophilization Formulation Development. Pharmaceutical Tech. Lyophilization. 2004, 10-18
- [12] Meister E, Ellnain M, Gieseler H. Collapse temperature measurement by freeze-dry microscopy and transferability to freeze drying processes: inluence of solute concentration on collapse behavior and effect on cycle design. AAPS annual meeting and exposition. Oct 29 – Nov 2, 2006, San Antonio, Texas, USA
- [13] Amin K, Dannenfelser RM, Zielinski J, Wang B. Lyophilization of polyethylene glycol mixtures. J Pharm Sci. 2004; 93(9):2244-9.
- [14] Chang BS, Randall CS. Use of subambient thermal analysis to optimize protein lyophilization. Cryobiology. 1992; 29: 632-656.

- [15] MacKenzie AP. The physico-chemical basis of the freeze drying process. Dev Biol Std. 1976; 36: 51-67.
- [16] Franks F. Freeze drying: From empiricism to predictability. Cryo-Letters. 1990; 11: 93-110.
- [17] Her LM, Nail SL. Measurement of glass transition temperatures of freeze-concentrated solutes by differential scanning calorimetry. Pharm Res. 1994; 11: 54-59.
- [18] MacKenzie AP. Basic principles of freeze drying for pharmaceuticals. Bull Par Drug Assoc. 1966; 20: 101-129.
- [19] Bellows RJ, King CJ. Freeze drying of aqueous solutions: Maximum allowable operating temperature, Cryobiology. 1972; 9: 559-561.
- [20] Shalaev EY, Kanev AN. Study of the solid-liquid state diagram of the water-glycine-sucrose system, Cryobiology. 1994; 31: 374-382.
- [21] Pikal MJ. Freeze drying, in Swarbrick J and Boylan JC (eds):Encyclopedia of Pharmaceutical Technology, Marcel Dekker Inc., New York, NY, 1992; 6: 275-303.
- [22] Trissel LA. Handbook on injectable drugs, American society of Hospital Pharmacists, Inc., 8th edition, 1994.